By Fineline Cube Broncus Medical Inc. (HKG: 2216) announced that its self-developed BroncTru disposable bronchoscopic dilation catheter has obtained the CE mark under the European Union Medical Device Regulation (EU MDR). The innovative device enables rapid whole-lung lesion diagnosis and treatment when used in combination with existing diagnostic and therapeutic bronchoscopic products, addressing diverse clinical needs across pulmonary medicine.
Regulatory Overview
| Item | Detail |
|---|---|
| Company | Broncus Medical Inc. (HKG: 2216) |
| Device | BroncTru disposable bronchoscopic dilation catheter |
| Regulatory Milestone | CE Mark under EU Medical Device Regulation (EU MDR) |
| Milestone Date | 27 Jul 2026 |
| Device Classification | Class IIa/IIb medical device (estimated under EU MDR) |
| Market Access | European Economic Area (EEA) |
Device Profile & Clinical Applications
- Primary Function: Bronchoscopic airway dilation for diagnostic and therapeutic access
- Key Innovation: Disposable design ensuring sterility and consistent performance
- Integration Capability: Compatible with multiple existing bronchoscopic platforms and techniques
- Versatility: Supports comprehensive lung intervention workflow from diagnosis to treatment
Diagnostic Applications
- EBUS-TTCB: Endobronchial ultrasound-guided transbronchial dilation catheter mediastinal lesion cryobiopsy
- EBUS-GS-TBLB: Ultrasound-guided disposable bronchoscopic dilation catheter localized biopsy
- TBNA: Transbronchial needle aspiration
- Cavity Procedures: Bronchoscopic lung cavity puncture biopsy and lavage
Therapeutic Applications
- Targeted Drug Delivery: Precise medication administration via bronchoscopic dilation catheters
- Ablation Procedures: Facilitation of bronchoscopic tumor ablation techniques
- Positioning Assistance: Bronchoscopic-assisted device positioning for complex interventions
Market Impact & Strategic Implications
- EU MDR Compliance: Achievement demonstrates Broncus Medical’s ability to meet stringent new European regulatory requirements, enhancing credibility in global markets
- Pulmonary Intervention Market: Addresses growing demand for minimally invasive lung diagnostics and therapeutics, with the global bronchoscopy devices market projected to reach €2.8 billion by 2030
- Workflow Integration Advantage: Unlike single-purpose devices, BroncTru’s versatility supports multiple procedures, potentially reducing procedural costs and inventory complexity for healthcare facilities
- Competitive Differentiation: Disposable design eliminates reprocessing requirements and associated infection risks, aligning with European healthcare safety priorities
- Global Expansion Pathway: CE Mark serves as springboard for regulatory submissions in other international markets, including UK, Middle East, and Asia-Pacific regions
- Revenue Diversification: Expands Broncus Medical’s portfolio beyond imaging technologies into therapeutic intervention devices, creating cross-selling opportunities
Forward‑Looking Statements
This brief contains forward-looking statements regarding regulatory approvals, market adoption, and commercial potential for BroncTru. Actual results may differ due to risks including competitive dynamics, reimbursement challenges, market acceptance, and regulatory compliance requirements in additional jurisdictions.-Fineline Info & Tech